Rituximab Treats Kidney Disorder

During a median follow-up of 29 months after treatment with the monoclonal antibody rituximab, 65 of 100 consecutive patients with idiopathic membranous nephropathy achieved complete remission (persistent proteinuria below 0.3 g/24 hours and a reduction in proteinuria greater than 50% from baseline) or partial remission (persistent proteinuria less than g/24 hours and a reduction in proteinuria greater than 50% from baseline).

Median time to remission was 7.1 months. Remission rates were similar between patients with or without previous immunosuppressive therapy, and the drug was well tolerated, according to a report in the Journal of the American Society of Nephrology 2012;23:1416-1425).

Loading links....
You must be a registered member of Renal and Urology News to post a comment.